נגישות
menu      
Advanced Search
Annals of Medicine
Sela, S., Department of Human Microbiology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel, Department of Human Microbiology, Sackler School of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel
Barzilai, A., Pediatric Infectious Diseases Unit, Chaim Sheba Medical Center, Tel-Hashomer Hospital, Tel-Aviv, Israel
Acute pharyngotonsillitis caused by β-haemolytic group A streptococcus (GAS) is a common childhood disease. Phenoxymethyl penicillin remains the drug of choice, as no resistance has been reported so far. Nevertheless, the failure of penicillin to eradicate streptococci from the throat occurs in up to 35% of patients with pharyngotonsillitis, and might present clinical concern. Various explanations have been proposed over the years to account for this perplexing phenomenon. Among these are coexistence of oropharyngeal β-lactamase-producing bacteria that degrade penicillin, growth interference by aerobic and anaerobic commensals, penicillin tolerance, reinfection, and poor antibiotic compliance. Although GAS has been considered an extracellular pathogen, recent studies have demonstrated that strains of this bacterium can internalize epithelial cells both in vitro and in vivo. The intracellular niche may protect the bacterium from penicillin that does not gain high intracellular concentration. In support of this hypothesis, GAS strains were shown to survive 4-7 days inside cultured epithelial cells. In addition, it was found that GAS strains isolated from patients with eradication failure harbour the internalization-associated gene, prtF1/sfbI, in higher prevalence than do strains recovered from patients with successful eradication. Thus, internalization and intracellular survival represent a novel explanation for penicillin eradication failure.
Powered by ClearMash Solutions Ltd -
Volcani treasures
About
Terms of use
Why do we fail with penicillin in the treatment of group A streptococcus infections?
31
Sela, S., Department of Human Microbiology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel, Department of Human Microbiology, Sackler School of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel
Barzilai, A., Pediatric Infectious Diseases Unit, Chaim Sheba Medical Center, Tel-Hashomer Hospital, Tel-Aviv, Israel
Why do we fail with penicillin in the treatment of group A streptococcus infections?
Acute pharyngotonsillitis caused by β-haemolytic group A streptococcus (GAS) is a common childhood disease. Phenoxymethyl penicillin remains the drug of choice, as no resistance has been reported so far. Nevertheless, the failure of penicillin to eradicate streptococci from the throat occurs in up to 35% of patients with pharyngotonsillitis, and might present clinical concern. Various explanations have been proposed over the years to account for this perplexing phenomenon. Among these are coexistence of oropharyngeal β-lactamase-producing bacteria that degrade penicillin, growth interference by aerobic and anaerobic commensals, penicillin tolerance, reinfection, and poor antibiotic compliance. Although GAS has been considered an extracellular pathogen, recent studies have demonstrated that strains of this bacterium can internalize epithelial cells both in vitro and in vivo. The intracellular niche may protect the bacterium from penicillin that does not gain high intracellular concentration. In support of this hypothesis, GAS strains were shown to survive 4-7 days inside cultured epithelial cells. In addition, it was found that GAS strains isolated from patients with eradication failure harbour the internalization-associated gene, prtF1/sfbI, in higher prevalence than do strains recovered from patients with successful eradication. Thus, internalization and intracellular survival represent a novel explanation for penicillin eradication failure.
Scientific Publication
You may also be interested in